{
  "nctId": "NCT01390272",
  "briefTitle": "Titrated Disease Management for Patients With Hypertension",
  "officialTitle": "Randomized Trial of Titrated Disease Management for Patients With Hypertension",
  "protocolDocument": {
    "nctId": "NCT01390272",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2016-03-04",
    "uploadDate": "2018-08-17T12:46",
    "size": 4967053,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT01390272/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 385,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2012-07-27",
    "completionDate": "2016-10-31",
    "primaryCompletionDate": "2016-10-31",
    "firstSubmitDate": "2011-07-06",
    "firstPostDate": "2011-07-11"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Age \\>= 18 years.\n* Assigned primary care provider in one of the clinics of the Durham VA Medical Center (VAMC) (including Community Based Outpatient Clinics for example - Hillandale Clinic and Greenville (CBOC)).\n* Had at least 1 primary care visit at the Durham VA or affiliated CBOC in the last year.\n* Diagnosis of hypertension requiring medication, as determined by: ICD 401.0, 401.1, or 401.9 for \\>= 2 outpatient encounters during the prior year and Received a prescription for at least 1 of the following classes of hypertensive medication in the previous year: 1) ACE inhibitors; 2) alpha blockers; 3) angiogenesis II inhibitors; 4) beta blockers; 5) calcium channel blockers; 6) diuretics; 7) antihypertensive combination; and/or 8) antihypertensives, other.\n* Out of control systolic blood pressure: Durham VAMC (including CBOCs or other affiliated clinics captured in the Durham VAMC electronic health record) outpatient BP measurements \\>= 150 mmHg for non-diabetic or \\>= 140 mmHg for diabetic patients over the last year and last systolic BP measurement \\>= 140 mmHg for non-diabetic or \\>= 130 mmHg for diabetic patients. If additional patients need to be approached to be offered the opportunity for further screening, non-diabetic patients with mean outpatient systolic BP of \\>= 140 mmHg or diabetic patients with mean outpatient systolic BP of \\>= 130 mmHg over the past year may be approached.\n\nPatients must indicate that they both:\n\n* Have a VA or affiliated clinic provider that they consider to be their main PCP.\n* Receive the majority of healthcare at the Durham VA Medical Center (or affiliated clinic - such as Hillandale or Greenville).\n\nExclusion Criteria:\n\n* Active diagnosis of psychosis.\n* Diagnosis of metastatic cancer.\n* Type 1 diabetes\n* Class IV congestive heart failure (CHF).\n* Currently receiving kidney dialysis or if estimated glomerular filtration rate (eGFR) levels are \\<= 15.\n* Chronic obstructive pulmonary disease (COPD) requiring oxygen.\n* Resident in nursing home or receiving home healthcare.\n* Patient is pregnant or reports planning to become pregnant in the next two years\n* At the time of potential enrollment, participating in another ongoing hypertension, diabetes, cholesterol, or cardiovascular disease clinical trial.\n* Planning to leave the area prior to the anticipated end of participation.\n* Inability or unwillingness to come to the Durham VAMC or affiliated clinic such as Hillandale or Greenville for baseline-, 6-, 12-, and 18-month study visits.\n* Does not have reasonable access to a telephone.\n* Does not speak English.\n* Severely impaired hearing or speech (Patients must be able to respond to phone calls.).\n* Severely impaired vision (Patients must be able to read mailed material).\n* Refusal or inability to provide informed consent and HIPAA authorization form.\n* Arm size \\> 50 cm\n* Unable to obtain (including by arm) valid blood pressure readings\n* Inadequate mental status to complete the protocol, as judged by five or more errors on the Short Portable Mental Status Questionnaire (SPMSQ).\n* Former, current or pending solid organ or bone marrow transplant patient.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Systolic Blood Pressure",
        "description": "Continuous change in systolic blood pressure was measured as the primary outcome. Mean systolic blood pressure was calculated by the average of 3 blood pressure measurements collected at the baseline study visits.",
        "timeFrame": "Baseline"
      },
      {
        "measure": "Systolic Blood Pressure",
        "description": "Continuous change in systolic blood pressure was measured as the primary outcome. Mean systolic blood pressure was calculated by the average of 3 blood pressure measurements collected at the 6- month study visits.",
        "timeFrame": "6 months"
      },
      {
        "measure": "Systolic Blood Pressure",
        "description": "Continuous change in systolic blood pressure was measured as the primary outcome. Mean systolic blood pressure was calculated by the average of 3 blood pressure measurements collected at the12-month study visits.",
        "timeFrame": "12 months"
      },
      {
        "measure": "Systolic Blood Pressure",
        "description": "Continuous change in systolic blood pressure was measured as the primary outcome. Mean systolic blood pressure was calculated by the average of 3 blood pressure measurements collected at the18- month study visits.",
        "timeFrame": "18 months"
      }
    ],
    "secondary": [
      {
        "measure": "Number of Participants With Hypertension Control",
        "description": "The investigators examined the difference in the degree of systolic BP control over the 18 months of the study between the intervention and control arms. Control was defined as SBP \\< 130mmHg for hypertensive patients with diabetes and \\< 140mmHg for patients without diabetes. Mean systolic blood pressure was calculated by the average of 3 blood pressure measurements collected at the baseline study visit.",
        "timeFrame": "Baseline"
      },
      {
        "measure": "Number of Participants With Hypertension Control",
        "description": "The investigators examined the difference in the degree of systolic BP control over the 18 months of the study between the intervention and control arms. Control was defined as SBP \\< 130mmHg for hypertensive patients with diabetes and \\< 140mmHg for patients without diabetes. Mean systolic blood pressure was calculated by the average of 3 blood pressure measurements collected at the 6-month study visit.",
        "timeFrame": "6 months"
      },
      {
        "measure": "Number of Participants With Hypertension Control",
        "description": "The investigators examined the difference in the degree of systolic BP control over the 18 months of the study between the intervention and control arms. Control was defined as SBP \\< 130mmHg for hypertensive patients with diabetes and \\< 140mmHg for patients without diabetes. Mean systolic blood pressure was calculated by the average of 3 blood pressure measurements collected at the 12-study visit.",
        "timeFrame": "12 months"
      },
      {
        "measure": "Number of Participants With Hypertension Control",
        "description": "The investigators examined the difference in the degree of systolic BP control over the 18 months of the study between the intervention and control arms. Control was defined as SBP \\< 130mmHg for hypertensive patients with diabetes and \\< 140mmHg for patients without diabetes. Mean systolic blood pressure was calculated by the average of 3 blood pressure measurements collected at the18- month study visit.",
        "timeFrame": "18 months"
      },
      {
        "measure": "Cost Effectiveness",
        "description": "One of our secondary research questions was: \"If the intervention results in greater reduction in SBP than the control group, is it cost effective?\"\n\nIntervention results did not show statistically significant differences between arms, therefore cost effectiveness analysis was not appropriate.\n\nWhile cost effectiveness was not analyzed because it was a null trial, the investigators would have used resource utilization and cost data from VA data sets to measure VA outpatient and inpatient utilization and costs by arms over 18 months. The investigators would have examined hypertension-related outpatient pharmacy prescription counts and costs in order to compare them to total outpatient pharmacy costs and the investigators would have examined inpatient utilization and costs.",
        "timeFrame": "Over 18 months of study intervention"
      },
      {
        "measure": "Number of Participants Who Did Not Achieve Medication Adherence",
        "description": "The investigators assessed adherence using patient self-report on a modified Morisky scale using 4 items:\n\n* Do you ever forget to take your blood pressure medicine?\n* Are you careless at times about taking your blood pressure medicine?\n* When you feel better do you sometimes stop taking you blood pressure medicine?\n* Sometimes if you feel worse when you take your blood pressure medicine, do you stop taking it? The scale is a Yes(0) or No (1) answer.\n\nA response of YES to any one of the 4 items indicated non-adherence, and responses of all no indicated adherence.\n\nThe numbers in the descriptive tables reflect number non-adherent.",
        "timeFrame": "Baseline"
      },
      {
        "measure": "Number of Participants Who Did Not Achieve Medication Adherence",
        "description": "The investigators assessed adherence using patient self-report on a modified Morisky scale using 4 items:\n\n* Do you ever forget to take your blood pressure medicine?\n* Are you careless at times about taking your blood pressure medicine?\n* When you feel better do you sometimes stop taking you blood pressure medicine?\n* Sometimes if you feel worse when you take your blood pressure medicine, do you stop taking it? The scale is a Yes(0) or No (1) answer.\n\nA response of YES to any one of the 4 items indicated non-adherence, and responses of all no indicated adherence.\n\nThe numbers in the descriptive tables reflect number non-adherent.",
        "timeFrame": "6 months"
      },
      {
        "measure": "Number of Participants Who Did Not Achieve Medication Adherence",
        "description": "The investigators assessed adherence using patient self-report on a modified Morisky scale using 4 items:\n\n* Do you ever forget to take your blood pressure medicine?\n* Are you careless at times about taking your blood pressure medicine?\n* When you feel better do you sometimes stop taking you blood pressure medicine?\n* Sometimes if you feel worse when you take your blood pressure medicine, do you stop taking it? The scale is a Yes(0) or No (1) answer.\n\nA response of YES to any one of the 4 items indicated non-adherence, and responses of all no indicated adherence.\n\nThe numbers in the descriptive tables reflect number non-adherent.",
        "timeFrame": "12 months"
      },
      {
        "measure": "Number of Participants Who Did Not Achieve Medication Adherence",
        "description": "The investigators assessed adherence using patient self-report on a modified Morisky scale using 4 items:\n\n* Do you ever forget to take your blood pressure medicine?\n* Are you careless at times about taking your blood pressure medicine?\n* When you feel better do you sometimes stop taking you blood pressure medicine?\n* Sometimes if you feel worse when you take your blood pressure medicine, do you stop taking it? The scale is a Yes(0) or No (1) answer.\n\nA response of YES to any one of the 4 items indicated non-adherence, and responses of all no indicated adherence.\n\nThe numbers in the descriptive tables reflect number non-adherent.",
        "timeFrame": "18 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 4,
      "secondaryCount": 9,
      "otherCount": 0,
      "totalCount": 13
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 99,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:14.264Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}